Dated: March 4, 2022

Tracey L. Thompson,

Acting Deputy Director, Office of Sustainable Fisheries, National Marine Fisheries Service. [FR Doc. 2022–05002 Filed 3–8–22; 8:45 am] BILLING CODE 3510–22–P

## DEPARTMENT OF COMMERCE

#### Patent and Trademark Office

[Docket No. PTO-P-2022-0009]

## Grant of Interim Extension of the Term of U.S. Patent No. 8,858,612; Reducer®

**AGENCY:** United States Patent and Trademark Office, Department of Commerce.

**ACTION:** Notice of interim patent term extension.

**SUMMARY:** The United States Patent and Trademark Office has issued an order granting a one-year interim extension of the term of U.S. Patent No. 8,858,612.

FOR FURTHER INFORMATION CONTACT: Ali Salimi, Senior Legal Advisor, Office of Patent Legal Administration, by telephone at 571–272–0909 or by email to *ali.salimi@uspto.gov.* 

**SUPPLEMENTARY INFORMATION:** Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to one year if the regulatory review is anticipated to extend beyond the expiration date of the patent.

On February 22, 2022, Neovasc Medical Ltd., the patent owner of record, timely filed an application under 35 U.S.C. 156(d)(5) for a third interim extension of the term of U.S. Patent No. 8,858,612. The patent claims methods of using a catheter delivered implantable device known by the tradename Reducer<sup>®</sup>. The application for patent term extension indicates that a Premarket Approval Application (PMA) P190035 was submitted to the Food and Drug Administration (FDA) on December 31, 2019.

Review of the patent term extension application indicates that, except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for one year as required by 35 U.S.C. 156(d)(5)(B). Because the regulatory review period will continue beyond the extended expiration date of the patent, March 27, 2022, interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate.

An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 8,858,612 is granted for a period of one year from the extended expiration date of the '612 patent.

## Robert Bahr,

Deputy Commissioner for Patents, United States Patent and Trademark Office. [FR Doc. 2022–04969 Filed 3–8–22; 8:45 am] BILLING CODE 3510–16–P

DEPARTMENT OF COMMERCE

#### Patent and Trademark Office

[Docket No.: PTO-P-2022-0003]

# Grant of Interim Extension of the Term of U.S. Patent No. 6,953,476; Reducer®

**AGENCY:** United States Patent and Trademark Office, Department of Commerce.

**ACTION:** Notice of interim patent term extension.

**SUMMARY:** The United States Patent and Trademark Office has issued an order granting a one-year interim extension of the term of U.S. Patent No. 6,953,476.

FOR FURTHER INFORMATION CONTACT: Ali Salimi, Senior Legal Advisor, Office of Patent Legal Administration, by telephone at 571–272–0909 or by email to *ali.salimi@uspto.gov.* 

**SUPPLEMENTARY INFORMATION:** Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to one year if the regulatory review is anticipated to extend beyond the expiration date of the patent.

On February 22, 2022, Neovasc Medical Ltd., the patent owner of record, timely filed an application under 35 U.S.C. 156(d)(5) for a third interim extension of the term of U.S. Patent No. 6,953,476. The patent claims a catheter delivered implantable device, Reducer<sup>®</sup>. The application for patent term extension indicates that a Premarket Approval Application (PMA) P190035 was submitted to the Food and Drug Administration (FDA) on December 31, 2019. Review of the patent term extension application indicates that, except for permission to market or use the product commercially, the subject patent would be eligible for

an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for one year as required by 35 U.S.C. 156(d)(5)(B). Because the regulatory review period will continue beyond the extended expiration date of the patent, March 27, 2022, interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate.

An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 6,953,476 is granted for a period of one year from the extended expiration date of the '476 patent.

#### Robert Bahr,

Deputy Commissioner for Patents, United States Patent and Trademark Office. [FR Doc. 2022–04970 Filed 3–8–22; 8:45 am] BILLING CODE 3510–16–P

# BUREAU OF CONSUMER FINANCIAL PROTECTION

[Docket No. CFPB-2022-0017]

#### Agency Information Collection Activities: Comment Request

**AGENCY:** Bureau of Consumer Financial Protection.

**ACTION:** Notice and request for comment.

**SUMMARY:** In accordance with the Paperwork Reduction Act of 1995 (PRA), the Consumer Financial Protection Bureau (CFPB or Bureau) requests the extension of the Office of Management and Budget's (OMB's) approval of the existing information collection titled "Electronic Fund Transfer Act (Regulation E)" approved under OMB Control Number 3170–0014.

**DATES:** Written comments are encouraged and must be received on or before April 8, 2022 to be assured of consideration.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/ PRAMain. Find this particular information collection by selecting "Currently under 30-day Review—Open for Public Comments" or by using the search function. In general, all comments received will become public records, including any personal information provided. Sensitive personal information, such as account numbers or Social Security numbers, should not be included.

**FOR FURTHER INFORMATION CONTACT:** Documentation prepared in support of this information collection request is available at *www.regulations.gov*. Requests for additional information should be directed to Anthony May, Paperwork Reduction Act Officer, at (202) 841–0544, or email: *CFPB\_PRA@ cfpb.gov.* If you require this document in an alternative electronic format, please contact *CFPB\_Accessibility@ cfpb.gov.* Please do not submit comments to these email boxes.

#### SUPPLEMENTARY INFORMATION:

*Title of Collection:* Electronic Fund Transfer Act (Regulation E).

OMB Control Number: 3170–0014. Type of Review: Extension of a currently approved information collection.

*Affected Public:* Businesses and other for-profit institutions.

*Estimated Number of Respondents:* 600,000.

*Estimated Total Annual Burden Hours:* 3,361,056.

Abstract: The Electronic Fund Transfer Act (EFTA), 15 U.S.C. 1693 et seq., requires accurate disclosure of the costs, terms, and rights relating to electronic fund transfer (EFT) services and remittance transfer services to consumers. Entities offering EFT services must provide consumers with full and accurate information regarding consumers' rights and responsibilities in connection with EFT services. These disclosures are intended to protect the rights of consumers using EFT services, such as automated teller machine (ATM) transfers, telephone bill-payment services, point-of-sale transfers at retail establishments, electronic check conversion, payroll cards, and preauthorized transfers from or to a consumer's account. EFTA also establishes error resolution procedures and limits consumer liability for unauthorized transfers in connection with EFT services. EFTA and Regulation E impose disclosure and other requirements on issuers and sellers of gift cards, gift certificates, and generaluse prepaid cards. Further, EFTA and Regulation E provide protections for consumers in the United States who send remittance transfers to persons in a foreign country. It also provides comprehensive protections for consumers who use "prepaid accounts." Tailored provisions governing disclosures, limited liability, error resolution, and periodic statements added new requirements regarding the posting of account agreements. Additionally, Regulations E regulates overdraft credit features offered in connection with prepaid accounts.

*Request for Comments:* The Bureau published a 60-day **Federal Register** notice on 12/16/2021 (86 FR 71453) under Docket Number: CFPB–2021–0021. The Bureau is soliciting

comments on: (a) Whether the collection of information is necessary for the proper performance of the functions of the Bureau, including whether the information will have practical utility; (b) The accuracy of the Bureau's estimate of the burden of the collection of information, including the validity of the methods and the assumptions used; (c) Ways to enhance the quality, utility, and clarity of the information to be collected; and (d) Ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Comments submitted in response to this notice will be submitted to OMB as part of its review of this request. All comments will become a matter of public record.

## Anthony May,

Paperwork Reduction Act Officer, Consumer Financial Protection Bureau. [FR Doc. 2022–04953 Filed 3–8–22; 8:45 am] BILLING CODE 4810–AM–P

## DEPARTMENT OF DEFENSE

## Office of the Secretary

## Defense Health Board; Notice of Federal Advisory Committee Meeting

**AGENCY:** Under Secretary of Defense for Personnel and Readiness, Department of Defense (DoD).

**ACTION:** Notice of Federal Advisory Committee meeting.

**SUMMARY:** The DoD is publishing this notice to announce that the following Federal Advisory Committee meeting of the Defense Health Board (DHB) will take place.

**DATES:** Open to the public Wednesday, March 30, 2022 from 12:00 p.m. to 4:00 p.m. Eastern time.

**ADDRESSES:** The meeting will be held by videoconference/teleconference. To participate in the meeting, see the Meeting Accessibility section for instructions.

#### FOR FURTHER INFORMATION CONTACT:

CAPT Gregory H. Gorman, U.S. Navy, 703–275–6060 (voice), gregory.h.gorman.mil@mail.mil (email). Mailing address is 7700 Arlington Boulevard, Suite 5101, Falls Church, Virginia 22042. Website: http:// www.health.mil/dhb. The most up-todate changes to the meeting agenda can be found on the website.

**SUPPLEMENTARY INFORMATION:** This meeting is being held under the provisions of the Federal Advisory Committee Act (FACA) (5 U.S.C.), the

Government in the Sunshine Act of 1976 (5 U.S.C. 552b), and 41 CFR 102–3.140 and 102–3.150.

Availability of Materials for the Meeting: Additional information, including the agenda, is available at the DHB website, http://www.health.mil/ dhb. A copy of the agenda or any updates to the agenda or the March 30, 2022, meeting will be available on the DHB website. Any other materials presented in the meeting may be obtained at the meeting.

Purpose of the Meeting: The DHB provides independent advice and recommendations to maximize the safety and quality of, as well as access to, health care for DoD health care beneficiaries. The purpose of the meeting is to provide briefings to DHB members on current issues related to military medicine and upcoming DHB taskings.

Agenda: The DHB meeting will be called to order and begin with both opening and administrative remarks at noon. At 12:30 p.m. the discussion will move to mental health care access and recess at 1:30 p.m. for a 15-minute break. At 1:45 p.m., the DHB will discuss racial and ethnic health care disparities and then at 2:45 p.m. conclude with a discussion on virtual health in the Military Health System. After closing remarks at 3:45 p.m., the meeting will adjourn at 4:00 p.m. Any changes to the agenda can be found at the link provided in this SUPPLEMENTARY **INFORMATION** section.

Meeting Accessibility: Pursuant to 5 U.S.C. 552b and 41 CFR 102-3.140 through 102-3.165, this meeting is open to the public from 12:00 p.m. to 4:00 p.m. on March 30, 2022. The meeting will be held by videoconference/ teleconference. The number of participants is limited and is on a firstcome basis. All members of the public who wish to participate must register by emailing their name, rank/title, and organization/company to dha.ncr.dhb.mbx.defense-healthboard@mail.mil or by contacting Ms. Pamela Shell at (703) 275-6012 no later than Wednesday, March 23, 2022. Once registered, the web address and audio number will be provided.

Special Accommodations: Individuals requiring special accommodations to access the public meeting should contact Ms. Pamela Shell at least five (5) business days prior to the meeting so that appropriate arrangements can be made. Written Comments and Statements: Any member of the public wishing to provide comments to the DHB related to its current taskings or mission may do so at any time in accordance with section 10(a)(3) of the